Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 4, 2026, 9:34 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 1,104 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Chronic Kidney Disease (CKD) Clear all
Completed No phase listed Observational

Evaluation of the Risk of NSF Following MultiHance Injection in Patients With Chronic Kidney Disease

NCT00600951
View directory record Official record
Conditions
Renal Insufficiency
Interventions
Not listed
Lead sponsor
Bracco Diagnostics, Inc
Industry
Eligibility
Not listed
Enrollment
366 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2013
U.S. locations
1
States / cities
Princeton, New Jersey
Source: ClinicalTrials.gov public record
Updated Nov 4, 2014 · Synced Oct 4, 2026, 9:34 AM EDT
Completed Phase 2 Interventional

Efficacy and Safety of Lanthanum Carbonate in Reducing Serum Phosphorus Levels in Subjects With Stage 3 and 4 Chronic Kidney Disease

NCT00234702
View directory record Official record
Conditions
Kidney Diseases
Interventions
Lanthanum carbonate, Placebo
Drug
Lead sponsor
Shire
Industry
Eligibility
18 Years and older
Enrollment
84 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2007
U.S. locations
10
States / cities
Los Angeles, California • Torrance, California • Thornton, Colorado + 7 more
Source: ClinicalTrials.gov public record
Updated Jun 8, 2021 · Synced Oct 4, 2026, 9:34 AM EDT
Completed Phase 4 Interventional

Diuretics and Volume Overload in Early CKD

NCT05171686
View directory record Official record
Conditions
Chronic Kidney Disease, Hypertension
Interventions
Diuretic augmentation (hydrochlorothiazide, chlorthalidone, furosemide, torsemide, or bumetanide)
Drug
Lead sponsor
VA Office of Research and Development
Federal
Eligibility
18 Years and older
Enrollment
49 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Sep 21, 2026 · Synced Oct 4, 2026, 9:34 AM EDT
Completed Not applicable Interventional

Community-Based Screening for Chronic Kidney Disease

NCT07747363
View directory record Official record
Conditions
Chronic Kidney Disease, Hypertension
Interventions
outpatient clinic kidney-protective care
Other
Lead sponsor
University of Texas at Austin
Other
Eligibility
18 Years to 70 Years
Enrollment
145 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2024
U.S. locations
1
States / cities
Austin, Texas
Source: ClinicalTrials.gov public record
Updated Aug 6, 2026 · Synced Oct 4, 2026, 9:34 AM EDT
Completed Phase 2 Interventional Results available

Phase 2b Study of KBP-5074 in Subjects With Uncontrolled Hypertension and Advanced Chronic Kidney Disease

NCT03574363
View directory record Official record
Conditions
Chronic Kidney Diseases, Hypertension
Interventions
KBP-5074 0.25 mg tablet, KBP-5074 0.5 mg tablet
Drug
Lead sponsor
KBP Biosciences
Industry
Eligibility
18 Years to 85 Years
Enrollment
162 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
2
States / cities
Princeton, New Jersey • Morrisville, North Carolina
Source: ClinicalTrials.gov public record
Updated Dec 30, 2025 · Synced Oct 4, 2026, 9:34 AM EDT
Completed Phase 4 Interventional Results available

Repeated-dose Safety, Efficacy, Pharmacokinetic and Pharmacodynamic of CTAP101, Immediate-release Calcifediol, High-dose Cholecalciferol, and Paricalcitol Plus Low-dose Cholecalciferol in Patients With Secondary Hyperparathyroidism, Chronic Kidney Disease 3-4 and Vitamin D Insufficiency

NCT03588884
View directory record Official record
Conditions
Secondary Hyperparathyroidism Due to Renal Causes, Vitamin D Insufficiency, CKD Stage 3, CKD Stage 4
Interventions
Calcifediol Oral Capsule, Calcifediol Oral Product, Cholecalciferol, Paricalcitol Oral Capsule
Drug
Lead sponsor
OPKO Health, Inc.
Industry
Eligibility
18 Years and older
Enrollment
69 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
3
States / cities
Garden Grove, California • Chicago, Illinois • West Bend, Wisconsin
Source: ClinicalTrials.gov public record
Updated Dec 9, 2022 · Synced Oct 4, 2026, 9:34 AM EDT
Completed Phase 2 Interventional

Defining The Role Of Dialysate Magnesium In Arrhythmogenicity On Dialysis

NCT00242164
View directory record Official record
Conditions
Chronic Kidney Disease, Arrhythmia
Interventions
Dialysate Magnesium (Concentration)
Drug
Lead sponsor
University of Michigan
Other
Eligibility
18 Years and older
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2006
U.S. locations
2
States / cities
Ann Arbor, Michigan • Livonia, Michigan
Source: ClinicalTrials.gov public record
Updated Dec 9, 2014 · Synced Oct 4, 2026, 9:34 AM EDT
Completed Not applicable Interventional Results available

Cholecalciferol (Vitamin D3) Therapy in Chronic Kidney Disease (CKD) Subjects

NCT00427037
View directory record Official record
Conditions
Chronic Kidney Disease, Vitamin D Deficiency
Interventions
Cholecalciferol, Placebo
Drug
Lead sponsor
Atlanta VA Medical Center
Federal
Eligibility
18 Years to 85 Years
Enrollment
34 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2013
U.S. locations
1
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Jul 22, 2015 · Synced Oct 4, 2026, 9:34 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Study to Evaluate the Pharmacokinetics and Metabolism of [14C] CR845 (Difelikefalin) in Patients With End Stage Renal Disease on Hemodialysis and in Healthy Subjects

NCT03947970
View directory record Official record
Conditions
Hemodialysis, Healthy
Interventions
[14C] CR845
Drug
Lead sponsor
Cara Therapeutics, Inc.
Industry
Eligibility
18 Years and older · Male only
Enrollment
12 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Jul 24, 2019 · Synced Oct 4, 2026, 9:34 AM EDT
Completed No phase listed Observational

Pathogenesis of Compromised Bone Quality and Mechanics in Chronic Kidney Disease

NCT03626246
View directory record Official record
Conditions
Chronic Kidney Disease, End Stage Kidney Disease, Chronic Kidney Disease Mineral and Bone Disorder, Renal Osteodystrophy, Secondary Hyperparathyroidism
Interventions
Kidney disease
Other
Lead sponsor
Columbia University
Other
Eligibility
40 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2020
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jul 13, 2021 · Synced Oct 4, 2026, 9:34 AM EDT
Completed Not applicable Interventional Results available

Metabolic Acidosis and Vascular Function in Patients With Chronic Kidney Disease

NCT02031770
View directory record Official record
Conditions
Metabolic Acidosis, Chronic Kidney Disease
Interventions
Sodium bicarbonate, Control
Drug · Other
Lead sponsor
University of Colorado, Denver
Other
Eligibility
40 Years to 70 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
1
States / cities
Aurora, Colorado
Source: ClinicalTrials.gov public record
Updated Sep 22, 2020 · Synced Oct 4, 2026, 9:34 AM EDT
Withdrawn No phase listed Observational Accepts healthy volunteers

Glomerular Filtration Rate (GFR) Reporting on Nephrology Referral Patterns by Internists

NCT00134797
View directory record Official record
Conditions
Chronic Kidney Disease
Interventions
Not listed
Lead sponsor
United States Naval Medical Center, San Diego
Federal
Eligibility
18 Years and older
Healthy volunteers
Accepts healthy volunteers
Timeline
2005 – 2006
U.S. locations
1
States / cities
San Diego, California
Source: ClinicalTrials.gov public record
Updated Aug 1, 2025 · Synced Oct 4, 2026, 9:34 AM EDT
Terminated Phase 3 Interventional Results available

Pediatric Chronic Kidney Disease Safety and Efficacy

NCT01277510
View directory record Official record
Conditions
Chronic Kidney Disease, Hyperparathyroidism, Hyperparathyroidism, Secondary, Kidney Disease, Secondary Hyperparathyroidism
Interventions
cinacalcet capsule, placebo, Standard of Care
Drug
Lead sponsor
Amgen
Industry
Eligibility
6 Years to 17 Years
Enrollment
43 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2011
U.S. locations
18
States / cities
Birmingham, Alabama • Los Angeles, California • San Francisco, California + 14 more
Source: ClinicalTrials.gov public record
Updated Jun 29, 2020 · Synced Oct 4, 2026, 9:34 AM EDT
Completed Phase 2 Interventional

A Study of AND017 to Treat Anemia in Non-dialysis-Dependent Chronic Kidney Disease (NDD-CKD) Patients

NCT05035641
View directory record Official record
Conditions
Renal Anemia
Interventions
AND017, Placebo
Drug
Lead sponsor
Kind Pharmaceuticals LLC
Industry
Eligibility
20 Years to 74 Years
Enrollment
113 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
7
States / cities
Northridge, California • Winter Park, Florida • Shreveport, Louisiana + 4 more
Source: ClinicalTrials.gov public record
Updated Oct 4, 2023 · Synced Oct 4, 2026, 9:34 AM EDT
Completed Phase 1 Interventional Results available

A Study of LY3113593 in Participants With Chronic Kidney Disease

NCT02604160
View directory record Official record
Conditions
Chronic Kidney Disease
Interventions
LY3113593, Placebo
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years and older
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
5
States / cities
Orlando, Florida • Indianapolis, Indiana • Shreveport, Louisiana + 2 more
Source: ClinicalTrials.gov public record
Updated Mar 21, 2019 · Synced Oct 4, 2026, 9:34 AM EDT
Terminated Phase 3 Interventional

A Study to Evaluate the Safety and Efficacy of Difelikefalin in Advanced Chronic Kidney Disease Patients With Moderate-to-Severe Pruritus

NCT05342623
View directory record Official record
Conditions
Chronic Kidney Diseases, Pruritus
Interventions
Difelikefalin 1 mg Oral Tablet, Placebo Oral Tablet
Drug
Lead sponsor
Cara Therapeutics, Inc.
Industry
Eligibility
18 Years to 85 Years
Enrollment
286 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
83
States / cities
Huntsville, Alabama • Phoenix, Arizona • Surprise, Arizona + 76 more
Source: ClinicalTrials.gov public record
Updated May 7, 2024 · Synced Oct 4, 2026, 9:34 AM EDT
Terminated Phase 2 Interventional Results available

Safety, Efficacy, PK and PD of CTAP101 (Calcifediol) ER Capsules for SHPT in HD Patients VDI

NCT03602261
View directory record Official record
Conditions
Secondary Hyperparathyroidism Due to Renal Causes, Chronic Kidney Diseases, Vitamin D Deficiency, Stage 5 Chronic Kidney Disease
Interventions
Calcifediol Oral Capsule, Placebo oral capsule
Drug
Lead sponsor
OPKO Health, Inc.
Industry
Eligibility
18 Years and older
Enrollment
44 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2021
U.S. locations
18
States / cities
Peoria, Arizona • Phoenix, Arizona • Cypress, California + 13 more
Source: ClinicalTrials.gov public record
Updated Apr 3, 2026 · Synced Oct 4, 2026, 9:34 AM EDT
Recruiting Not applicable Interventional

Effects of Replacing High Protein Foods in People With Chronic Kidney Disease

NCT07105670
View directory record Official record
Conditions
Chronic Kidney Disease Stage 3
Interventions
Controlled dietary intervention
Other
Lead sponsor
Indiana University
Other
Eligibility
40 Years to 70 Years
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
1
States / cities
West Lafayette, Indiana
Source: ClinicalTrials.gov public record
Updated Aug 11, 2026 · Synced Oct 4, 2026, 9:34 AM EDT
Completed Phase 4 Interventional Results available

Trial to Optimize Mineral Outcomes in Dialysis Patients

NCT01100723
View directory record Official record
Conditions
Secondary Hyperparathyroidism, Chronic Kidney Disease
Interventions
Cinacalcet, active vitamin D analogue
Other
Lead sponsor
University of Colorado, Denver
Other
Eligibility
18 Years and older
Enrollment
92 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
1
States / cities
Lynchburg, Virginia
Source: ClinicalTrials.gov public record
Updated Jan 2, 2017 · Synced Oct 4, 2026, 9:34 AM EDT
Completed Phase 3 Interventional Results available

A Research Study to Find Out How Semaglutide Works in the Kidneys Compared to Placebo, in People With Type 2 Diabetes and Chronic Kidney Disease (the REMODEL Trial)

NCT04865770
View directory record Official record
Conditions
Diabetes Mellitus, Type 2, Chronic Kidney Disease
Interventions
Semaglutide, Placebo (Semaglutide)
Drug
Lead sponsor
Novo Nordisk A/S
Industry
Eligibility
18 Years and older
Enrollment
106 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
20
States / cities
Tucson, Arizona • Los Angeles, California • National City, California + 14 more
Source: ClinicalTrials.gov public record
Updated Feb 10, 2026 · Synced Oct 4, 2026, 9:34 AM EDT
Not listed Not applicable Interventional

The Effects of Frailty on Chronic Kidney Disease

NCT02775305
View directory record Official record
Conditions
Sarcopenia, Chronic Kidney Disease
Interventions
Frail
Behavioral
Lead sponsor
San Francisco Veterans Affairs Medical Center
Federal
Eligibility
18 Years to 100 Years
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2016
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated May 17, 2016 · Synced Oct 4, 2026, 9:34 AM EDT
Completed Phase 3 Interventional Results available

Evaluation of the Effects of Canagliflozin on Renal and Cardiovascular Outcomes in Participants With Diabetic Nephropathy

NCT02065791
View directory record Official record
Conditions
Diabetes Mellitus, Type 2, Diabetic Nephropathy
Interventions
Canagliflozin, Placebo
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
30 Years and older
Enrollment
4,401 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2018
U.S. locations
152
States / cities
Birmingham, Alabama • Montgomery, Alabama • Tempe, Arizona + 149 more
Source: ClinicalTrials.gov public record
Updated Dec 5, 2019 · Synced Oct 4, 2026, 9:34 AM EDT
Completed Phase 3 Interventional Results available

Ferric Carboxymaltose (FCM) Assessment in Subjects With Iron Deficiency Anaemia and Non-dialysis-dependent Chronic Kidney Disease (NDD-CKD)

NCT00994318
View directory record Official record
Conditions
Iron Deficiency Anaemia, Chronic Kidney Disease
Interventions
FCM (Ferric carboxymaltose) high ferritin target, FCM (Ferric carboxymaltose) low ferritin target, Oral Iron (Ferrous sulphate)
Drug
Lead sponsor
Vifor Pharma
Industry
Eligibility
18 Years and older
Enrollment
626 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2014
U.S. locations
1
States / cities
Wilmington, North Carolina
Source: ClinicalTrials.gov public record
Updated May 20, 2014 · Synced Oct 4, 2026, 9:34 AM EDT
Active, not recruiting Early Phase 1 Interventional

Subclinical Primary Aldosteronism in Diabetes At-Risk for Kidney Disease

NCT06190158
View directory record Official record
Conditions
Type 2 Diabetes, Chronic Kidney Diseases
Interventions
Oral sodium suppression test, Saline suppression test, Captopril suppression test, Dexamethasone suppression test, Cosyntropin stimulation test
Diagnostic Test
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
18 Years to 80 Years
Enrollment
125 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2029
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Aug 13, 2026 · Synced Oct 4, 2026, 9:34 AM EDT